Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-19
2010-02-16
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
07662846
ABSTRACT:
The present invention encompasses compounds of Formula (I) and Formula (II) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
REFERENCES:
patent: 4412995 (1983-11-01), Bell et al.
patent: 2005/0054700 (2005-03-01), Scanlan et al.
patent: 2005/0256315 (2005-11-01), Ali et al.
patent: WO 03/061651 (2003-07-01), None
patent: WO 03/086294 (2003-10-01), None
patent: WO 2004/026248 (2004-04-01), None
patent: WO 2004/075840 (2004-09-01), None
Smith et al., “Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity”, Bioorganic&Medicinal chemistry Letters, 15 (2005) 2926-2931.
Schacke et al.,, “Selective Glucocorticoid Receptor Agonists (SEGRAs): Novel ligands with an improved therapeutic index”, Molecular and Cellular Endocrinology (2007), doi:10.1016/j.mce.2007.05.014, 9 pages.
Zips et al., “In vitro and in vivo evaluation of new anticancer agents”, in vivo, 19 (2005), 1-7 (8 pages).
Barnes, P.J., “Mediators of Chronic Obstructive Pulmonary Disease”, Pharmacological Reviews, vol. 56, No. 4, p. 515-548.
http://en.wikipedia.org/wiki/Racemic—mixture (1 PAGE ONLY).
McCulloch et al. “Signalling Platforms that Modulate the Inflammatory Response: New Targets for Drug Development”, Nature Reviews Drug Discovery (2006), vol. 5, pp. 864-876.
Shacter et al., “Chronic Inflammation and Cancer”, Oncology (2002), vol. 16, p. 217-232.
Hirschmann, et al.., “Synthesis and Structure of Steroidal 4-Pregneno[3,2-c]Pyrazoles. A Novel Class of Potent Anti-Inflammatory Steroids”, J. Am. Chem. Soc., vol. 85, pp. 120-122 (1963).
Hirschmann et al., “Methylated Steroids. IV. 6,16a-Dimethyl-Hydrocortisone and Related Compounds”, J. Am. Chem. Soc., vol. 85, pp. 236-238, (1963).
Hirschmann, et al., “Synthesis and Structure of Steroidal Pregn-4-eno-and 5a-Pregnano[3,2-c]pyrazoles. A Novel Class of Potent Anti-Inflammatory Steroids”, J. Am. Chem. Soc., vol. 86, pp. 1520-1527 (1964).
Hirschmann, et al., “Synthesis of Pregn-4-eno[3,2-c]pyrazoles Related to 9a-Fluoro-16a-methylcortisol”, J. Med. Chem., vol. 7, pp. 352-355, (1964).
Robert Newton, “Molecular mechanisms of glucocorticoid action: what is important?”, Thorax, vol. 55, pp. 603-613, (2000).
Schane, et al., “Glucocorticoid/Antiinflammatory activities of Nonsteroidal Phenylpyrazoles in the Rat”, Steroids, vol. 45, No. 2, pp. 171-185, (1985).
Ali Amjad
Balkovec James M.
Beresis Richard
Colletti Steven L.
Graham Donald W.
Camara Valerie J.
Loewe Sun Jae Y
Merck Sharp & Dohme Corp.
Shameem Golam M. M.
Zhao Yong
LandOfFree
Selective spirocyclic glucocorticoid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective spirocyclic glucocorticoid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective spirocyclic glucocorticoid receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195208